Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Challenges in CAR T-cell therapy

Renier Brentjens • 4 Sep 2020
SOHO 2020
General CAR-T

Renier J. Brentjens, MD, PhD, of Memorial Sloan-Kettering Cancer Center, New York, NY, outlines the major challenges in CAR T-cell therapies including remission and relapse rate, cost, as well as mitigating associated toxicities. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Renier Brentjens

3:12
New CAR designs
Renier Brentjens • 3 Sep 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals